Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs
- 1 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 42 (2) , 177-182
- https://doi.org/10.1097/01.qai.0000221683.44940.62
Abstract
Background: Liver damage is frequently seen in HIV-positive subjects, often resulting from coinfection with hepatitis B and/or C viruses (HCV), alcohol abuse, etc. However, the etiology of liver disease still remains unknown for a small subset of individuals. Methods: Cryptogenic liver disease (CLD) was defined as persistently elevated aminotransferases levels in the absence of hepatitis C and/or B viruses replication and of other common causes of liver disease (alcohol, medications, etc). We identified cases initially meeting this definition by examining all HIV-positive subjects attended during the year 2004 in 2 large HIV clinics in Spain. Their clinical charts were retrospectively reviewed, and their assessment completed when needed to rule out other less frequent causes of liver disease. The stage of liver fibrosis was assessed by liver biopsy and/or elastography. To assess which factors could be associated with CLD, HIV-positive controls were chosen and matched by age, gender, and CD4 status. Results: CLD was diagnosed in 17 (0.5%) out of 3200 HIV-positive patients. Their mean age was 43 years, 82.4% were male, and 76% had acquired HIV through homosexual relationships. The mean time from HIV diagnosis was >15 years, and all patients had been exposed to antiretroviral therapy. Nevirapine, stavudine, and didanosine were the drugs more frequently used by this subset of patients. None of them had liver function test abnormalities before initiating antiretroviral therapy. Advanced liver fibrosis (F3-F4 Metavir scores) was recognized in 10 (58.8%) individuals, and 9 (52.9%) had developed symptomatic liver complications, including ascites (8), portal thrombosis (6), variceal bleeding (5), and encephalopathy (2). In the case-control analysis, prolonged didanosine exposure was the only independent predictor of developing CLD in this population. Conclusions: CLD is an uncommon condition in HIV-positive individuals and might be associated with prolonged didanosine exposure. It may evolve causing severe liver complications, with variceal bleeding and portal thrombosis being particularly frequent.Keywords
This publication has 46 references indexed in Scilit:
- Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan Analyte-Specific Reagent Assay and Comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 AssaysJournal of Clinical Microbiology, 2005
- Real time TaqMan PCR detection and quantitation of HBV genotypes A–G with the use of an internal quantitation standardJournal of Clinical Virology, 2004
- Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabineHepatology, 2004
- Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)AIDS, 2003
- Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected PatientsAIDS Research and Human Retroviruses, 2001
- Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serologyJournal of Hepatology, 2001
- Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001
- Survival after introduction of HAART in people with known duration of HIV-1 infectionThe Lancet, 2000
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Hepatitis in children with acquired immune deficiency syndromeGastroenterology, 1986